{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:24:01Z","timestamp":1778495041869,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1736,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1124\/jpet.119.261008","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T21:35:20Z","timestamp":1582752920000},"page":"122-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome"],"prefix":"10.1016","volume":"373","author":[{"given":"Alexander","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Grafton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew D.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinkun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison J.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zania","family":"Stamataki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Sargent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter R.","family":"Guzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas M.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.261008_bib1","doi-asserted-by":"crossref","first-page":"5729","DOI":"10.1111\/bph.13347","article-title":"The concise guide to PHARMACOLOGY 2015\/16: overview","volume":"172","author":"Alexander","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib2","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bmj.294.6580.1129","article-title":"Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist","volume":"294","author":"Anderson","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1124\/jpet.119.261008_bib3","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","article-title":"Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Andresen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.119.261008_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrd1961","article-title":"The IBS market","volume":"5","author":"Ashburn","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.119.261008_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2005.09.031","article-title":"Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome","volume":"130","author":"Atkinson","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261008_bib6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/24750573.2017.1387403","article-title":"Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report","volume":"28","author":"Aydin","year":"2017","journal-title":"Psychiatr Clin Psychopharmacol"},{"key":"10.1124\/jpet.119.261008_bib7","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.261008_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0028-3908(94)00159-P","article-title":"5-Hydroxytryptamine3 receptor antagonism modulates a noxious visceral pseudoaffective reflex","volume":"34","author":"Banner","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.261008_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1476-5381.1995.tb13263.x","article-title":"Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity","volume":"114","author":"Banner","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/gut.42.1.42","article-title":"Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study","volume":"42","author":"Bearcroft","year":"1998","journal-title":"Gut"},{"key":"10.1124\/jpet.119.261008_bib11","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0028-3908(01)00074-0","article-title":"Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A\/3B receptors","volume":"41","author":"Brady","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.119.261008_bib12","first-page":"453","article-title":"Economic burden of irritable bowel syndrome with diarrhea: retrospective analysis of a U.S. commercially insured population","volume":"23","author":"Buono","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1124\/jpet.119.261008_bib13","first-page":"550","article-title":"Medical therapies in the pipeline for irritable bowel syndrome","volume":"13","author":"Camilleri","year":"2017","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1124\/jpet.119.261008_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/gutjnl-2016-313425","article-title":"Dietary and pharmacological treatment of abdominal pain in IBS","volume":"66","author":"Camilleri","year":"2017","journal-title":"Gut"},{"key":"10.1124\/jpet.119.261008_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S126143","article-title":"Developments in the treatment of carcinoid syndrome - impact of telotristat","volume":"14","author":"Chan","year":"2018","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/jpet.119.261008_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","article-title":"Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data","volume":"101","author":"Chang","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/jpet.119.261008_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000109984","article-title":"Effects of the novel 5-HT3 agonist MKC-733 on the rat, mouse and Guinea pig digestive tract","volume":"81","author":"Chetty","year":"2008","journal-title":"Pharmacology"},{"key":"10.1124\/jpet.119.261008_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1517\/13543784.14.2.185","article-title":"Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea","volume":"14","author":"Chey","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.119.261008_bib19","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1124\/jpet.119.261008_bib20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1046\/j.1365-2036.2003.01797.x","article-title":"Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans","volume":"18","author":"Coleman","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.119.261008_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1124\/mol.108.049684","article-title":"General anesthetics sensitize the capsaicin receptor transient receptor potential V1","volume":"74","author":"Cornett","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/MOG.0000000000000411","article-title":"New therapies in Irritable Bowel Syndrome: what works and when","volume":"34","author":"Craig","year":"2018","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1124\/jpet.119.261008_bib23","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjp.0705762","article-title":"Role of serotonin in the pathophysiology of the irritable bowel syndrome","volume":"141","author":"Crowell","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib24","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1111\/bph.12856","article-title":"Experimental design and analysis and their reporting: new guidance for publication in BJP","volume":"172","author":"Curtis","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib25","first-page":"637","article-title":"The malignant carcinoid syndrome","volume":"137","author":"Davis","year":"1973","journal-title":"Surg Gynecol Obstet"},{"key":"10.1124\/jpet.119.261008_bib26","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S2468-1253(16)30022-X","article-title":"Functional gastrointestinal disorders: what\u2019s new for Rome IV?","volume":"1","author":"Drossman","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1124\/jpet.119.261008_bib27","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261008_bib28","doi-asserted-by":"crossref","first-page":"30799","DOI":"10.1074\/jbc.274.43.30799","article-title":"The pharmacological and functional characteristics of the serotonin 5-HT(3A) receptor are specifically modified by a 5-HT(3B) receptor subunit","volume":"274","author":"Dubin","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.261008_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1542-3565(04)00726-8","article-title":"Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome","volume":"3","author":"Dunlop","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/jpet.119.261008_bib30","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/nrdp.2016.14","article-title":"Irritable bowel syndrome","volume":"2","author":"Enck","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/jpet.119.261008_bib31","first-page":"416","article-title":"Drug evaluation: pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease","volume":"8","author":"Evangelista","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.119.261008_bib32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.gastro.2010.03.032","article-title":"Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients","volume":"139","author":"Faure","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261008_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.4158\/EP172000.OR","article-title":"Lanreotide therapy in carcinoid syndrome: prospective analysis of patient-reported symptoms in patients responsive to prior octreotide therapy and patients na\u00efve to somatostatin analogue therapy in the elect phase 3 study","volume":"24","author":"Fisher","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1124\/jpet.119.261008_bib34","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00406-014-0502-z","article-title":"Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis","volume":"264","author":"Fond","year":"2014","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1124\/jpet.119.261008_bib35","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/jpet.119.261008_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/CEG.S123621","article-title":"Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea","volume":"10","author":"Fragkos","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1124\/jpet.119.261008_bib37","first-page":"3077","article-title":"Expression and clinical significance of 5-HT and 5-HT3R in the intestinal mucosa of patient with diarrhea-type irritable bowel syndrome","volume":"17","author":"Fu","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1124\/jpet.119.261008_bib38","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2710.2005.00695.x","article-title":"Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study","volume":"30","author":"Fujita","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"10.1124\/jpet.119.261008_bib39","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00535-016-1165-5","article-title":"Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study","volume":"51","author":"Fukudo","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1124\/jpet.119.261008_bib40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gutjnl-2013-305989","article-title":"A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea","volume":"63","author":"Garsed","year":"2014","journal-title":"Gut"},{"key":"10.1124\/jpet.119.261008_bib41","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/apt.15420","article-title":"Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron","volume":"50","author":"Gunn","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/jpet.119.261008_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1124\/jpet.119.261008_bib43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1254\/jphs.FP0070620","article-title":"Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome","volume":"104","author":"Hirata","year":"2007","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.119.261008_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/gut.50.4.471","article-title":"The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers","volume":"50","author":"Houghton","year":"2002","journal-title":"Gut"},{"key":"10.1124\/jpet.119.261008_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0140-6736(92)93273-P","article-title":"Ondansetron in carcinoid syndrome","volume":"340","author":"Jacobsen","year":"1992","journal-title":"Lancet"},{"key":"10.1124\/jpet.119.261008_bib46","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1093\/hmg\/ddn195","article-title":"First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome","volume":"17","author":"Kapeller","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1124\/jpet.119.261008_bib47","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1016\/S0016-5085(09)60701-0","article-title":"1003 A coding variant in the serotonin receptor 3C subunit is associated with diarrhea-predominant irritable bowel syndrome","volume":"136","author":"Kapeller","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261008_bib48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/cne.22525","article-title":"Serotonin receptor diversity in the human colon: expression of serotonin type 3 receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E","volume":"519","author":"Kapeller","year":"2011","journal-title":"J Comp Neurol"},{"key":"10.1124\/jpet.119.261008_bib49","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1301537","article-title":"Ondansetron for diarrhea associated with neuroendocrine tumors","volume":"368","author":"Kiesewetter","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.119.261008_bib50","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1053\/j.gastro.2011.03.011","article-title":"The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome","volume":"140","author":"Kilpatrick","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261008_bib51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1749-6632.1994.tb17296.x","article-title":"Metastatic carcinoid tumors and the malignant carcinoid syndrome","volume":"733","author":"Kvols","year":"1994","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/jpet.119.261008_bib52","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.119.261008_bib53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/2327-6924.12387","article-title":"Diarrhea-predominant irritable bowel syndrome: diagnosis, etiology, and new treatment considerations","volume":"28","author":"Lacy","year":"2016","journal-title":"J Am Assoc Nurse Pract"},{"key":"10.1124\/jpet.119.261008_bib54","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/acsmedchemlett.5b00157","article-title":"Molecular property design: does everyone get it?","volume":"6","author":"Leeson","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.119.261008_bib55","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1124\/mol.118.113530","article-title":"Modeling and mutational analysis of the binding mode for the multimodal antidepressant drug vortioxetine to the human 5-HT3A receptor","volume":"94","author":"Ladefoged","year":"2018","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib56","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261008_bib57","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1053\/j.gastro.2005.02.005","article-title":"Serotonin excites neurons in the human submucous plexus via 5-HT3 receptors","volume":"128","author":"Michel","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.119.261008_bib58","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.bcp.2004.06.034","article-title":"Identification and importance of N-glycosylation of the human 5-hydroxytryptamine3A receptor subunit","volume":"68","author":"Monk","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib59","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/bph.12213","article-title":"5-Chloroindole: a potent allosteric modulator of the 5-HT3 receptor","volume":"169","author":"Newman","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1530\/ERC-17-0455","article-title":"Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial","volume":"25","author":"Pavel","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1124\/jpet.119.261008_bib61","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/0140-6736(92)91235-Z","article-title":"Ondansetron in carcinoid syndrome","volume":"339","author":"Platt","year":"1992","journal-title":"Lancet"},{"key":"10.1124\/jpet.119.261008_bib62","first-page":"1","article-title":"Summary health statistics for U.S. adults: National Health Interview Survey, 2007","volume":"240","author":"Pleis","year":"2009","journal-title":"Vital Health Stat 10"},{"key":"10.1124\/jpet.119.261008_bib63","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1111\/bph.13638","article-title":"Novel mechanism of modulation at a ligand-gated ion channel; action of 5-Cl-indole at the 5-HT3 A receptor","volume":"173","author":"Powell","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.119.261008_bib64","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MCG.0000000000000653","article-title":"World gastroenterology organisation global guidelines irritable bowel syndrome: a global perspective update september 2015","volume":"50","author":"Quigley","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"10.1124\/jpet.119.261008_bib65","first-page":"645","article-title":"Treatment of diarrhea in carcinoid syndrome with ondansetron, tropisetron, and clonidine","volume":"90","author":"Schw\u00f6rer","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1124\/jpet.119.261008_bib66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0924-977X(01)00099-2","article-title":"Effects of the selective activation of 5-HT3 receptors on sleep: a polysomnographic study in healthy volunteers","volume":"11","author":"Staner","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1124\/jpet.119.261008_bib67","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12916-016-0761-9","article-title":"Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis","volume":"14","author":"Tricco","year":"2016","journal-title":"BMC Med"},{"key":"10.1124\/jpet.119.261008_bib68","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0959-8049(98)00009-4","article-title":"Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome","volume":"34","author":"Wymenga","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1124\/jpet.119.261008_bib69","doi-asserted-by":"crossref","first-page":"e0172846","DOI":"10.1371\/journal.pone.0172846","article-title":"Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zheng","year":"2017","journal-title":"PLoS One"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524258560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.261008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:55:44Z","timestamp":1739973344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524258560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0022356524258560"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.261008","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.261008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s).","name":"copyright","label":"Copyright"}]}}